This week we highlight some promising clinical research in the pancreatic cancer space.Daraxonrasib has shown OS benefit vs. chemo in the 2nd-line setting of metastatic pancreatic cancer compared to investigator's choice chemotherapy. Hopefully, we will get the abstract soon and publication shortly thereafter. A personalized mRNA vaccine for early-stage pancreatic cancer has some encouraging results (for those patients who mounted a sizable immune response to the vaccine).Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm